Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Biotech
BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed
BMS formed a broad partnership with Hengrui, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines.
Nick Paul Taylor
May 12, 2026 1:56am
Kailera plans $528.5 million IPO to support obesity assets
Apr 13, 2026 1:10pm
Merck KGaA drops pipeline asset from SpringWorks buyout
Mar 5, 2026 4:33pm
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Feb 10, 2026 9:25am
Braveheart pays $65M to challenge BMS for heart disease market
Sep 5, 2025 9:05am
GSK strengthens COPD offering via $12B biobucks Hengrui deal
Jul 28, 2025 4:36am
